drugset / Trial / NCT03066622

Olanzapine for Acute Headaches

NCT03066622

Phase 4 Completed 122 enrolled HealthPartners Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is a prospective, randomized, feasibility trial with the primary aim of comparing how well oral rapidly dissolving olanzapine controls primary headache pain when compared to the current treatment strategies used in emergency departments which often require intravenous or intramuscular medications.

Timeline

Start
2016-07
Primary completion
2018-05-17
Completion
2018-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 5 mg Oral

Indications